Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.75 |
| ▸ | DPP4 | P27487 | 6/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | LAP3 | P28838 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL18051147 | 1.00 | SLC7A5 (0.75) | SLC7A5DPP4SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL23149812 | 1.00 | SLC7A5 (0.75) | SLC7A5DPP4SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL28422139 | 1.00 | SLC7A5 (0.75) | SLC7A5DPP4SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL6295413 | 0.90 | SLC7A5 (0.75) | SLC7A5DPP4SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL9066603 | 0.90 | SLC7A5 (0.75) | SLC7A5DPP4SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL28116054 | 0.89 | — | — | |
| Valine SCHEMBL2217538 | 0.89 | — | — | |
| Valine SCHEMBL27604279 | 0.89 | SLC7A5 (0.94) | SLC7A5DPP4SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL6358549 | 0.89 | SLC7A5 (0.94) | SLC7A5DPP4SLC1A3SLC1A2SLC1A1 | |
| Valine SCHEMBL11014861 | 0.88 | SLC7A5 (0.71) | SLC7A5DPP4SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112595783-A | Method for detecting multiple antibiotics in livestock and poultry excrement based on magnetic nanocomposite | 山东省农业科学院农业质量标准与检测技术研究所 | 2021-04-02 | — | — | CN | claimed |
| CN-112305105-A | Method for measuring content of chemical components in plums | 西藏农牧学院 | 2021-02-02 | — | — | CN | claimed |
| CN-110511204-A | The preparation method of benzyl cyanide | TOPHARMAN SHANGHAI CO LTD | 2019-11-29 | — | — | CN | claimed |
| CN-107045020-A | A kind of method of N content of nitrosamines in complete detection meat products | 广西壮族自治区食品药品检验所 | 2017-08-15 | — | — | CN | claimed |
| CN-118258932-A | Method for determining triethanolamine in starting material SM2 of nicorandil bulk drug | 重庆华邦胜凯制药有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-117607285-A | Method for detecting concentration of NTM (negative temperature coefficient) disease drug in blood plasma by using triple quadrupole tandem mass spectrometry | 上海康黎医学检验所有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20230126662-A1 | SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-04-27 | — | — | US | disclosed |
| CN-115160387-B | Novel method for synthesizing compound arginine diglycoside AFG in red ginseng | 吉林农业大学 | 2023-03-10 | — | — | CN | disclosed |
| CN-115073361-A | Rosin diterpenoid compound and preparation method and application thereof | 广东药科大学 | 2022-09-20 | — | — | CN | disclosed |
| CN-115073538-A | Novel method for synthesizing compound arginine fructoside AF in ginseng | 吉林农业大学 | 2022-09-20 | — | — | CN | disclosed |
| CN-110988163-B | Method for separating and determining levocetirizine hydrochloride and genotoxic impurity E thereof by HPLC method | 重庆华邦胜凯制药有限公司 | 2022-04-19 | — | — | CN | disclosed |
| WO-2021133563-A1 | SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2021-07-01 | — | — | WO | disclosed |
| CN-106146332-A | Separate and measure Linezolid raw material X3 and the method for process contaminants X2 thereof | 重庆华邦胜凯制药有限公司 | 2016-11-23 | — | — | CN | disclosed |
| CN-105954419-A | Method for separating and determining levocetirizine hydrochloride and enantiomer thereof through HPLC method | 重庆华邦胜凯制药有限公司 | 2016-09-21 | — | — | CN | disclosed |
| CN-105873612-A | Engineered anti-DLL 3 conjugates and methods of use | 施特姆森特克斯股份有限公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-105030687-A | Medicine A317491 nanometer particle and application and preparation thereof | ZHANGJIAGANG INST IND TECHNOLOGIES SOOCHOW UNIV | 2015-11-11 | — | — | CN | disclosed |
| CN-103705470-B | Methylprednisolone-loading nanoparticles as well as preparation method and application thereof | UNIV NANTONG | 2015-06-17 | — | — | CN | disclosed |
| CN-103705470-A | Methylprednisolone-loading nanoparticles as well as preparation method and application thereof | UNIV NANTONG | 2014-04-09 | — | — | CN | disclosed |
| EP-0579738-A1 | IMPROVED PROCESS FOR PREPARING PHENYL ESTERS OF SUBSTITUTED ACIDS. | DU PONT (US) | 1994-01-26 | — | — | EP | disclosed |
| WO-1992016492-A1 | IMPROVED PROCESS FOR PREPARING PHENYL ESTERS OF SUBSTITUTED ACIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126662-A1 | SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC2R, MC1R, MC3R | SLC7A5 3872/4885DPP4 1374/4885SLC1A3 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.